Search

everythinglearnresearchcommunity

for

Search:↓

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.

Diagnosing mycosis fungoides, a rare skin cancer, is difficult in elderly adults and requires careful examination to avoid mistaking it for less serious skin conditions.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.

The document concludes that understanding how the skin's immune system and inflammation work is complex and requires more research to improve treatments for skin diseases.

Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

Transplant success has improved with better immunosuppressive drugs and donor matching.

Cancer therapy can cause various skin problems, including hair loss, skin darkening, painful hand-foot syndrome, and severe skin damage.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

A woman's ovarian tumor causing high testosterone was successfully removed, and her symptoms improved.

Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.

Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

An elderly Chinese man lost all his hair after taking a new heart medication.

Folliculotropic mycosis fungoides has a worse prognosis than other types, with survival rates varying significantly based on subtype and organ involvement.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

The document tests knowledge and decision-making in hematology through multiple-choice questions.